Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes
necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop
cancer cells from dividing so they stop growing or die. Combining imatinib mesylate and
chemotherapy may kill more cancer cells.
PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate plus cytarabine in
treating patients who have newly diagnosed chronic myeloid leukemia.